# Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer

> **NCT01488552** · PHASE1,PHASE2 · COMPLETED · sponsor: **Pancreatic Cancer Research Team** · enrollment: 60 (actual)

## Conditions studied

- Stage IV Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** nab-paclitaxel
- **DRUG:** FOLFIRINOX
- **GENETIC:** Immunohistochemistry (IHC) Analysis
- **DRUG:** Metformin
- **DRUG:** mFOLFIRI

## Key facts

- **NCT ID:** NCT01488552
- **Lead sponsor:** Pancreatic Cancer Research Team
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2015-08
- **Final completion:** 2016-08
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2016-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01488552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01488552, "Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01488552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*